Comprehensive Cancer Institute of Huntsville

Huntsville, Alabama 35801

0 studies enrolling now · 33 studies all time

What they study most

Anemia, Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Lung Cancer, Metastatic Cancer, Oral Complications

Studies at this site

• Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy — Completed
• Melatonin and Radiation Therapy in Treating Patients With Brain Metastases — Completed
• Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer — Completed
• Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer — Completed
• External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer — Completed
• Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum — Completed
• Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme — Completed
• Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme — Completed
• Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer — Completed
• Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases — Completed
• Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer — Completed
• Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy — Completed
• Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer — Completed
• Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer — Completed
• Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord — Completed
• Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme — Completed
• Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer — Completed
• Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer — Completed
• Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer — Completed
• Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer — Completed
• Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer — Status unconfirmed
• Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer — Completed
• Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer — Completed
• Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer — Completed
• Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer — Completed
• Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases — Completed
• Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer — Completed
• Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery — Completed
• Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma — Withdrawn before enrolling
• Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma — Completed
• Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma — Completed
• Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer — Completed
• Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen — Completed